TG003: Selective Clk Family Kinase Inhibitor for Alternative Splicing and Cancer Research

Executive Summary: TG003 is a small molecule inhibitor with high selectivity for the Cdc2-like kinase (Clk) family, used primarily in pre-mRNA splicing regulation research (APExBIO). It inhibits Clk1, Clk2, and Clk4 at nanomolar concentrations, with IC₅₀ values of 20 nM, 200 nM, and 15 nM, respectively, and shows poor activity against Clk3 (>10 μM). TG003 also suppresses casein kinase 1 activity and is ATP-competitive. In cellular and in vivo models, it reversibly inhibits SR protein phosphorylation and modulates nuclear speckle localization, affecting alternative splicing events (Jiang et al., 2024). TG003 is widely used for mechanistic studies of splicing, platinum resistance in ovarian cancer, and exon-skipping therapy research (FUT-175.com).

Biological Rationale

The Cdc2-like kinase family (Clk1–4) regulates the phosphorylation of serine/arginine-rich (SR) proteins, which direct spliceosome assembly and alternative exon selection during pre-mRNA splicing (Jiang et al., 2024). Aberrant Clk activity is implicated in developmental disorders, cancer progression, and chemoresistance, particularly in ovarian cancer where Clk2 overexpression is associated with platinum resistance (Jiang et al., 2024). Selective inhibition of Clk kinases enables mechanistic dissection of splicing regulation, provides a means to modulate exon usage, and supports drug discovery efforts targeting alternative splicing in disease. TG003, developed and supplied as a solid by APExBIO, is designed to facilitate these investigations by offering high selectivity and potency toward Clk1, Clk2, and Clk4, while sparing Clk3 and most non-Clk kinases (APExBIO product page).

Mechanism of Action of TG003 Cdc2-like kinase (Clk) inhibitor

TG003 acts as an ATP-competitive inhibitor of Clk1/Sty, binding the ATP pocket with a K_i of 0.01 μM (Bestatin.com). It blocks kinase-mediated phosphorylation of SR proteins, such as SF2/ASF, in cell-free and in vivo systems. This leads to reversible suppression of SR protein phosphorylation and disruption of their nuclear speckle localization. The downstream effect is altered splice site selection, resulting in shifts in exon inclusion/exclusion and modulation of transcript diversity. TG003 also inhibits casein kinase 1 (CK1), albeit with lower selectivity, and is structurally distinct from other splicing modulators. These properties make it suitable for dissecting Clk-dependent splicing pathways in both basic and translational research.

Evidence & Benchmarks

• TG003 inhibits Clk1 (IC₅₀: 20 nM), Clk2 (IC₅₀: 200 nM), Clk4 (IC₅₀: 15 nM), with poor activity against Clk3 (IC₅₀: >10 μM) (APExBIO).
• In vitro, TG003 competitively inhibits ATP binding to Clk1/Sty with a K_i of 0.01 μM and suppresses phosphorylation of SF2/ASF (Jiang et al., 2024).
• Cellular assays show TG003 reversibly inhibits SR protein phosphorylation and alters nuclear speckle localization in HeLa cells (TSU-68.com).
• In Xenopus embryos, TG003 modulates splicing site selection and can rescue developmental abnormalities caused by Clk overexpression (APExBIO).
• TG003 is soluble in DMSO (≥12.45 mg/mL) and ethanol (≥14.67 mg/mL with ultrasound), but insoluble in water (APExBIO).
• Clk2 is upregulated in ovarian cancer and confers resistance to platinum-based chemotherapy; Clk2 inhibition restores chemosensitivity (Jiang et al., 2024).

Applications, Limits & Misconceptions

TG003 is a validated tool for research on:

• Alternative splicing modulation in cancer, neuronal, and developmental models.
• Exon-skipping therapy studies, including Duchenne muscular dystrophy (DMD) preclinical models (JIB-04.com).
• Pathway mapping of Clk-mediated phosphorylation and mRNA processing.
• Resistance mechanisms in platinum-based chemotherapy for ovarian cancer (Jiang et al., 2024).

TG003's selectivity profile is robust, but researchers should be aware of the following boundaries and misconceptions:

Common Pitfalls or Misconceptions

• TG003 does not efficiently inhibit Clk3 at physiologically relevant concentrations (IC₅₀ >10 μM).
• It is not recommended for use in aqueous buffers due to poor solubility; DMSO or ethanol with ultrasonic treatment is required (APExBIO).
• Long-term storage of TG003 solutions is not advised; prepare fresh aliquots for each experiment.
• TG003 is not a pan-kinase inhibitor; its activity is limited to Clk1, Clk2, Clk4, and CK1 with little off-target activity reported.
• Effectiveness in in vivo models is context-dependent and may not translate across all species or tissues.

This article extends the practical focus of 'TG003 (SKU B1431): Solving Real-World Clk Inhibition…' by providing new quantitative benchmarks and clarifying the selectivity boundaries of TG003 in both in vitro and in vivo systems. For more in-depth workflow scenarios, see 'TG003 Cdc2-like kinase (Clk) inhibitor (SKU B1431): Scenario…', which addresses experimental troubleshooting and best practices for platinum resistance and alternative splicing assays.

Workflow Integration & Parameters

TG003 (SKU B1431) is supplied by APExBIO as a solid and should be stored at -20°C (APExBIO product page). For assays, prepare a 10 mM stock in DMSO and dilute to a 10 μM final concentration for cellular applications. Use ethanol with ultrasonic treatment for higher solubility if needed. Avoid water as a solvent. Use solutions promptly after preparation to avoid loss of potency. For in vitro kinase or splicing assays, titrate concentrations to optimize signal/noise while minimizing off-target effects. TG003 is compatible with HeLa, mouse, and Xenopus models, but results may vary by cell type and species. Always confirm target engagement by monitoring SR protein phosphorylation or alternative splicing patterns using validated antibodies or RT-PCR protocols. Consult 'Improving Pre-mRNA Splicing Research with TG003…' for example protocols and troubleshooting tips.

Conclusion & Outlook

TG003 remains a reference compound for dissecting Clk family kinase function and studying alternative splicing regulation. Its high selectivity for Clk1, Clk2, and Clk4—coupled with robust effects in cellular and animal models—support its continued use in platinum resistance research, cancer biology, and exon-skipping therapy development. As new splicing modulators and Clk-targeted therapies emerge, TG003 provides a benchmark for comparison and a tool for basic mechanistic investigations. For full product details and ordering information, refer to the TG003 Cdc2-like kinase (Clk) inhibitor page at APExBIO.